CC
FDMT icon

Centiva Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Centiva Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-358,863
Closed -$7.22M – 1309
2021
Q3 		$7.22M Buy
+358,863
New +$10.2M 0.45% 38

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Centiva Capital's FDMT Position: Q4 2021 in Review

Centiva Capital sold out of 4D Molecular Therapeutics (FDMT) in Q4 2021, closing a stake of 358,863 shares — an estimated $7.22M sold.

Centiva Capital first reported a position in FDMT in Q3 2021 and held it in 1 quarter. The position peaked at $7.22M in Q3 2021. 77 funds tracked by Wall St. Rank hold FDMT as of Q4 2021.

  • Centiva Capital reported no remaining 4D Molecular Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Centiva Capital sold 358,863 4D Molecular Therapeutics shares in Q4 2021, an estimated $7.22M.
  • Centiva Capital first reported a position in 4D Molecular Therapeutics in Q3 2021 and held it in 1 quarter.
  • Centiva Capital's 4D Molecular Therapeutics position peaked at $7.22M in Q3 2021.
  • 77 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2021.

Based on Centiva Capital's 13F filing for Q4 2021, filed 14 Feb 2022.